EA202091295A1 - Препарат - Google Patents

Препарат

Info

Publication number
EA202091295A1
EA202091295A1 EA202091295A EA202091295A EA202091295A1 EA 202091295 A1 EA202091295 A1 EA 202091295A1 EA 202091295 A EA202091295 A EA 202091295A EA 202091295 A EA202091295 A EA 202091295A EA 202091295 A1 EA202091295 A1 EA 202091295A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug
polysorbate
glycine
binds
antibody
Prior art date
Application number
EA202091295A
Other languages
English (en)
Inventor
Сандрин Дюрран
Эндрю Джеффри Йейтс
Original Assignee
Юсб Биофарма Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Биофарма Срл filed Critical Юсб Биофарма Срл
Publication of EA202091295A1 publication Critical patent/EA202091295A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям, содержащим антитело или его фрагмент, которое связывает IL-17A и IL-17F, и сочетание глицина, ацетатного буфера с pH 4,6-5,5 и полисорбата 80.
EA202091295A 2017-11-23 2018-11-13 Препарат EA202091295A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1719447.3A GB201719447D0 (en) 2017-11-23 2017-11-23 Pharmaceutical composition
PCT/EP2018/081129 WO2019101582A1 (en) 2017-11-23 2018-11-13 Formulation

Publications (1)

Publication Number Publication Date
EA202091295A1 true EA202091295A1 (ru) 2020-09-03

Family

ID=60950516

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091295A EA202091295A1 (ru) 2017-11-23 2018-11-13 Препарат

Country Status (18)

Country Link
US (2) US11857625B2 (ru)
EP (1) EP3713602A1 (ru)
JP (1) JP6955632B2 (ru)
KR (1) KR20200090829A (ru)
CN (1) CN111511399A (ru)
AR (1) AR113534A1 (ru)
BR (1) BR112020009866A2 (ru)
CA (1) CA3082832C (ru)
CL (1) CL2020001307A1 (ru)
CO (1) CO2020006120A2 (ru)
EA (1) EA202091295A1 (ru)
GB (1) GB201719447D0 (ru)
IL (1) IL274719B1 (ru)
MX (1) MX2020004747A (ru)
MY (1) MY194682A (ru)
RU (1) RU2020120547A (ru)
SG (1) SG11202004601YA (ru)
WO (1) WO2019101582A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
CN113769082A (zh) * 2020-06-10 2021-12-10 上海君实生物医药科技股份有限公司 抗il-17a抗体药物组合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0614100A2 (pt) 2005-08-03 2011-03-09 Immunogen Inc formulações de imunoconjugado lìquidas
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
SG182304A1 (en) 2009-12-29 2012-08-30 Hoffmann La Roche Antibody formulation
PT3295957T (pt) 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
CN102946861B (zh) 2010-03-01 2016-01-20 西托戴恩有限公司 浓缩蛋白制剂及其用途
EA037392B1 (ru) * 2010-05-14 2021-03-23 Эмджен Инк. Композиции с высокой концентрацией антител
FR2962650B1 (fr) 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
TWI616204B (zh) * 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
LT2663577T (lt) * 2011-01-14 2017-07-25 Ucb Biopharma Sprl Antikūnas, surišantis il-17a ir il-17f
US20150150979A1 (en) * 2012-06-21 2015-06-04 Ucb Pharma, S.A. Pharmaceutical formulation
WO2016070062A2 (en) * 2014-10-31 2016-05-06 Genentech, Inc. Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN116059350A (zh) * 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
WO2017180594A1 (en) 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
ES2905917T3 (es) 2016-09-14 2022-04-12 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo que se une específicamente a IL-17A y fragmento funcional del mismo

Also Published As

Publication number Publication date
CL2020001307A1 (es) 2020-10-16
RU2020120547A (ru) 2021-12-23
CA3082832A1 (en) 2019-05-31
IL274719B1 (en) 2024-06-01
JP2021504321A (ja) 2021-02-15
BR112020009866A2 (pt) 2020-11-17
EP3713602A1 (en) 2020-09-30
US11857625B2 (en) 2024-01-02
GB201719447D0 (en) 2018-01-10
MY194682A (en) 2022-12-14
AU2018371056A1 (en) 2020-06-04
WO2019101582A1 (en) 2019-05-31
CA3082832C (en) 2023-07-18
SG11202004601YA (en) 2020-06-29
IL274719A (en) 2020-07-30
AR113534A1 (es) 2020-05-13
US20210106683A1 (en) 2021-04-15
JP6955632B2 (ja) 2021-10-27
KR20200090829A (ko) 2020-07-29
MX2020004747A (es) 2020-08-20
CO2020006120A2 (es) 2020-05-29
CN111511399A (zh) 2020-08-07
RU2020120547A3 (ru) 2021-12-23
US20240123065A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
EA202091295A1 (ru) Препарат
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
BR112015022260A2 (pt) anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA202191763A1 (ru) Бифункциональная молекула анти-pd-1/sirp
CR20190208A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
BR112016026811A2 (pt) formulação de anticorpo
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
EA202192405A1 (ru) Составы антител против il-36r
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
CY1123231T1 (el) Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
EA201991876A1 (ru) Антитела против фактора d и их применения
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
MY194084A (en) Interferon beta antibodies and uses thereof
CL2020002597A1 (es) Métodos para preparar composiciones proteicas estables
EA202092723A1 (ru) Композиции и способы, касающиеся иммунной толерантности
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
MA55285A (fr) Anticorps ciblant c5ar
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
EA202090945A1 (ru) Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его